By Darya Korsunskaya
MOSCOW, April 19 Russia's government commission
on foreign investment has turned down U.S. group Abbott
Laboratories' request to buy Russian vaccine maker
Petrovax, the head of Russia's competition regulator said on
"The commission has reviewed the question about the sale to
U.S. company Abbott of Petrovax Pharm. As a result of very
lengthy discussion the U.S. company was denied to make this
deal," Igor Artemyev, head of the Federal Anti-Monopoly Service
(FAS), told reporters.
Artemyev said the decision was made in order to protect the
country's national security interests and took into account
He added the government would consider including vaccine
production in its list of so-called strategic sectors deemed to
be important to to national security, which would imply
restrictions on foreign ownership.
"The commission's decision is not a decision against the
Abbott company and even more so not against the United States.
This is a decision of a strategic character," said Artemyev.
Abbott Laboratories applied for permission to buy Petrovax
last year and according to media reports the deal was valued at
A spokeswoman for Abbott, Irina Gushchina, said the company
had not received any official information regarding the state of
"We understand that the Russian Governmental Commission on
Control of Foreign Investments is meeting today. We have not
received any official information on the outcome of the
meeting," she said, declining to comment further.